Triptan Study Will Evaluate Benefits Of Internet Studies, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The proposed feasibility study examines the use of the Internet to conduct a study of the prescribing practices of triptans, but additional studies would be done before regulatory action is taken.
You may also be interested in...
NEJM, JAMA Editorials Give Opposing Opinions Of Mandatory HPV Vaccination
Two of the leading medical journals are offering opposing viewpoints on mandatory human papilloma virus vaccination, with experts contributing perspective pieces that directly reflect the larger political and social division over the issue
FDA’s Arcoxia Decision Offers New Evidence Of Conservative Review Stance
FDA's "not approvable" action on Merck's Vioxx follow-on Arcoxia for the treatment of symptoms of osteoarthritis could be indicative of a conservative regulatory climate at the agency
House Bill Banning “Reverse Settlements” Would Give FTC Exemption Power
A bill introduced by Rep. Bobby Rush, D-Ill., banning "reverse" settlements between brand and generic companies would give the Federal Trade Commission the power to allow any such agreement it deems furthers market competition